United Therapeutics (NASDAQ:UTHR) Announces Quarterly Earnings Results, Misses Expectations By $0.30 EPS

United Therapeutics (NASDAQ:UTHR) announced its quarterly earnings results on Wednesday. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30), FiscalAI reports. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The company had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. During the same quarter last year, the company posted $7.16 EPS. The company’s quarterly revenue was up 4.1% compared to the same quarter last year.

Here are the key takeaways from United Therapeutics’ conference call:

• United Therapeutics reported record third-quarter revenue of $833 million, including record Tyvaso revenue of $504 million. Management attributed growth to sustained demand, stronger commercial execution, higher dosing and expanded field-force reach; October referrals also reached a monthly record.
• A court decision upholding the company’s intellectual property and a settlement with Liquidia remove PH-ILD from YUTREPIA’s label and bar its promotion for that indication. Management expects limited near-term patient switching, while emphasizing new prescriptions and market expansion as the main Tyvaso growth opportunity.
• The planned soft mist inhaler NDA filing has been pushed from year-end 2026 to 2027 after FDA discussions identified a need for additional supporting data, delaying a potential product opportunity.
• Ralinepag’s FDA application remains under review with a June 24, 2027 PDUFA date, but its API supplier has an Official Action Indicated compliance status. The company is pursuing remediation and says it has contingency plans, though the issue could pose a regulatory or supply risk.
• The FDA indicated that bioequivalence data would not be sufficient to support filing the triple oral pill; the company is evaluating alternative development and filing approaches, with no timeline disclosed.

United Therapeutics Stock Up 1.2%

United Therapeutics stock traded up $7.17 during mid-day trading on Wednesday, reaching $608.49. 928,869 shares of the company’s stock were exchanged, compared to its average volume of 557,224. The business’s fifty day simple moving average is $530.53 and its 200 day simple moving average is $531.77. United Therapeutics has a one year low of $432.53 and a one year high of $614.23. The firm has a market capitalization of $26.10 billion, a PE ratio of 21.77, a P/E/G ratio of 4.32 and a beta of 0.49.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on UTHR shares. BTIG Research lifted their price objective on shares of United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a report on Wednesday, October 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $850.00 price target on shares of United Therapeutics in a research report on Monday, October 26th. Leerink Partners raised their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research report on Monday, October 19th. Finally, Raymond James Financial set a $720.00 price target on shares of United Therapeutics in a report on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $674.00.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 4.1% year over year to $832.5 million, beating analyst expectations of about $781 million. BTIG Research raised its price target to $768 from $728 and maintained a Buy rating. United Therapeutics beats Q3 sales expectations BTIG Research ratings
• Positive Sentiment: The company announced a buyout of Pfizer’s royalty interest related to ralinepag, a therapy being developed for pulmonary arterial hypertension. Ending the royalty obligation could improve the economics of the therapy if it is commercialized. United Therapeutics buys out Pfizer royalties
• Negative Sentiment: Quarterly EPS of $5.71 fell short of analyst expectations and declined from $7.16 a year earlier; reports also noted lower net income. The earnings miss may offset some of the boost from the revenue beat. United Therapeutics Q3 earnings miss estimates
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares, about 2.84% of her direct stake, but retained 324,443 shares. The sale may attract attention, though it does not by itself indicate a change in the company’s outlook. CEO share sale report

Insiders Place Their Bets

In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at $170,968,483.28. This represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 401,528 shares of company stock valued at $211,631,836 over the last 90 days. 8.60% of the stock is currently owned by insiders.

United Therapeutics announced that its Board of Directors has approved a share buyback program on Thursday, October 22nd that allows the company to buy back $2 billion in shares. This buyback authorization allows the biotechnology company to purchase up to 8.3% of its shares through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.